By immunohistochemistry, Yao et al. found that receptor tyrosine kinase (RTK) members ErbB2, ErbB3, and c-Met were indeed differentially overexpressed in samples from CRC patients, leading to constitutive activation of RTK signaling pathways. Here, MET is linked to colorectal carcinoma.